医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis

2019年04月25日 PM04:00
このエントリーをはてなブックマークに追加


 

BALLERUP, Denmark

LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005072/en/

The post-hoc analysis of the AMAGINE-2 and AMAGINE-3 studies – which included 3,712 people with moderate-to-severe psoriasis – shows that 90% of patients treated with brodalumab who achieved PASI 100 also experienced sustained PASI 100. In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI 100 also experienced sustained PASI 100. Study authors measured ‘sustained PASI 100’ as the time to inadequate response, based on a static physician’s global assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week period at or after week 16.1

Because the sub-populations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the study authors did not apply statistical comparisons.

Newer treatments for moderate-to-severe psoriasis have made it possible for patients to completely clear their skin, but the disease fluctuates over time, so we wanted to explore how fast and for how long patients can count on having complete skin clearance,” said Professor Lluís Puig, Director, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona. “These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab. That difference can have a big impact on patients’ quality of life.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005072/en/

CONTACT

LEO Pharma A/S
Trine Juul Wengel, Global External Communications
tewdk@leo-pharma.com
Tel.:
+45 72 60 86 18

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生